Pascal Soriot: Okay. Mark Purcell, Morgan Stanley. Mark, over to you.
Mark Purcell: Pascal; two questions. One on Dato-DXd, the second one on Farxiga. On Data DSD Tropo, there appears to be a bit of a debate at the moment given the layers to the top line data disclosure which could be positive, it could be negative. But if we look back at PANTumoRO1 and the non-small cell lung cancer, cohort, the PFS was 6.9 months. And I don’t believe we’ve seen an update since the ASCO 2021 data. Clearly, the duration of exposure was quite low, 5 months because these are very fell patients, over 60% of them were third line plus. So as you sort of go forward in these patients a better — likely to better tolerate mucositis and stemititis and things like that. How should we think about PFS benefit in the second line setting?
I think we all well understand that dose should show a 4- to 5-month benefit in this setting. But how should we think about the PFS benefit as you come forward in line? And should we expect these data to present at ASCO or ESMO this year? And then second, in terms of Farxiga, it would be really useful for — to help us understand how far Sega revenues are split between diabetes and heart failure, obviously, we recognize there’s overlap between those but it’s more in terms of thinking about the future. When we look at the sort of range of combination opportunities you have on Slide 24, it would be great to understand sort of where the bigger opportunities lie. And based on Phase II data, where you believe you will drive most differentiation versus SGL2 monotherapy.
Pascal Soriot: Thanks, Mark. So Susan back to you again. And Ruud, do you want to cover the second one in terms of the potential?
Susan Galbraith: So thanks, Marc, for the question. Well, you clearly a very familiar with the lung cohort from . As you say, it’s close to a 7-month median PFS in a more heavily pretreated patient population. So again, 1 would expect that in an earlier line, you might do a little better than that but that’s — we’ll have to wait and see for the child date to read out. And then in terms of the timing, it’s an event-driven trial. We’ve guided to the first half that’s what we’re still expecting to see. And of course, depending on the timing, we’ll then make the data available at an upcoming congress dependent on those timing.
Ruud Dobber: Okay. And regarding your question about the split market, it’s a bit of a difficult question because there are substantial differences across different geographies, primarily in the emerging markets, the international markets is still heavily driven by diabetes. But if you look at the United States and Europe, it’s roughly 2/3 of the patients are coming from heart failure and CKD. But rightly mentioning there is a substantial overlap. Moving forward, we truly believe that there is a substantial opportunity for our combinations in the heart failure segment and the chronic kidney disease segment. Both segments are very well underserved and we believe is the excellent profile of Farxiga and potentially also, of course, then the antihypertensive effects of at as well as 997 7, we have a unique opportunity to further expand that population in both CKD and heart failure.
Pascal Soriot: Thanks, Rudd. Mene, I understand that you — unless Mene, you wanted to add something or?
